Stock ScreenerStock IdeasBiotech BreakthroughsBest Biotech Stocks To Buy NowTop biotech stocks that analysts expect to be profitable within the next 3 years
Stock ScreenerStock IdeasBiotech Breakthroughs
Industry: Biotechnology
Forecast Earnings Growth: Positive
| Ticker | Company | Zen Rating | Financials | Market Cap | ROE | ROA | ROCE | ROIC | D/E | Current Ratio | Gross Margin | Profit Margin | Operating Margin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| CORT | CORCEPT THERAPEUTICS INC | $12.56B | 8.30% | 6.40% | 0.74% | 0.90% | 0.26 | 2.86 | 98.30% | 6.50% | 0.65% | ||
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | $3.16B | 15.10% | 6.50% | 13.15% | 12.00% | 1.22 | 2.92 | 91.10% | 6.10% | 9.30% | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | $29.40B | 93.60% | 15.80% | 27.79% | 22.30% | 3.11 | 3.06 | 79.70% | 16.80% | 23.41% | ||
| KNSA | KINIKSA PHARMACEUTICALS INTERNATIONAL PLC | $5.91B | 13.70% | 10.10% | 15.76% | 24.30% | 0.37 | 3.90 | 89.80% | 9.60% | 13.59% | ||
| VCEL | VERICEL CORP | $2.06B | 6.90% | 5.00% | 5.71% | 6.20% | 0.36 | 5.04 | 74.60% | 7.90% | 8.40% | ||
| RPRX | ROYALTY PHARMA PLC | $32.87B | 8.30% | 4.10% | 6.13% | 4.50% | 1.03 | 2.80 | 100.00% | 32.10% | 46.37% | ||
| KRYS | KRYSTAL BIOTECH INC | $9.54B | 19.30% | 17.70% | 16.50% | 27.80% | 0.10 | 8.32 | 94.60% | 54.80% | 51.45% | ||
| HALO | HALOZYME THERAPEUTICS INC | $12.47B | 180.60% | 16.50% | 27.03% | 24.60% | 16.96 | 2.71 | 82.40% | 24.90% | 36.28% | ||
| ZVRA | ZEVRA THERAPEUTICS INC | $593.24M | 32.80% | 20.50% | 29.52% | 42.70% | 0.39 | 5.17 | 95.50% | 42.80% | 55.12% | ||
| TGTX | TG THERAPEUTICS INC | $8.31B | 72.30% | 33.60% | 10.14% | 10.30% | 1.71 | 4.27 | 82.40% | 55.20% | 17.40% | ||
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.07B | 1.20% | 0.80% | 2.31% | 3.70% | 0.85 | 2.39 | 76.10% | 2.10% | 6.83% | ||
| JAZZ | JAZZ PHARMACEUTICALS PLC | $15.30B | 21.40% | 8.20% | 10.15% | 13.40% | 1.31 | 1.78 | 88.40% | 20.40% | 19.53% | ||
| MDXG | MIMEDX GROUP INC | $669.04M | 2.60% | 2.00% | 4.06% | 10.20% | 0.30 | 5.33 | 78.80% | 1.80% | 2.77% | ||
| EXEL | EXELIXIS INC | $14.47B | 42.50% | 32.00% | 48.56% | 49.90% | 0.35 | 3.46 | 96.50% | 35.30% | 42.51% | ||
| ADMA | ADMA BIOLOGICS INC | $2.18B | 39.60% | 26.60% | 37.03% | 38.00% | 0.68 | 6.97 | 64.70% | 33.00% | 43.98% | ||
| LGND | LIGAND PHARMACEUTICALS INC | $6.04B | 20.10% | 11.70% | 11.41% | 15.40% | 1.26 | 31.18 | 95.40% | 67.90% | 84.03% | ||
| VRTX | VERTEX PHARMACEUTICALS INC | $127.93B | 23.30% | 16.90% | 22.49% | 31.00% | 0.35 | 3.19 | 86.00% | 35.00% | 41.96% | ||
| UTHR | UNITED THERAPEUTICS CORP | $23.23B | 20.20% | 18.00% | 23.97% | 31.10% | 0.13 | 5.73 | 86.10% | 41.60% | 50.25% | ||
| TECH | BIO-TECHNE CORP | $11.35B | 8.90% | 7.10% | 10.33% | 20.40% | 0.23 | 4.55 | 65.80% | 15.00% | 20.60% | ||
| HRMY | HARMONY BIOSCIENCES HOLDINGS INC | $2.31B | 20.10% | 14.10% | 22.36% | 52.00% | 0.37 | 3.48 | 75.40% | 18.90% | 26.53% | ||
| REGN | REGENERON PHARMACEUTICALS INC | $75.69B | 13.80% | 10.60% | 14.42% | 15.10% | 0.32 | 3.34 | 84.90% | 27.90% | 33.61% | ||
| VCYT | VERACYTE INC | $3.68B | 8.60% | 8.00% | 8.15% | 49.40% | 0.07 | 9.16 | 71.70% | 20.40% | 20.65% | ||
| SPRO | SPERO THERAPEUTICS INC | $69.30M | 16.20% | 12.60% | 17.24% | 227.80% | 0.19 | 6.12 | 100.00% | 15.70% | 16.26% | ||
| INCY | INCYTE CORP | $23.37B | 29.60% | 22.60% | 30.02% | 87.80% | 0.24 | 4.59 | 92.60% | 27.70% | 33.85% |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.